Bioxytran (QB) Stock Price - BIXT

Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Bioxytran Inc (QB) BIXT OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.035 -5.83% 0.565 0.57 0.565 0.57 0.60 16:11:12
Bid Price Ask Price Spread Spread % News
0.32 0.90 0.58 64.44% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4 2,720 $ 0.568235 $ 1,546 3,485 0.20 - 1.95
Last Trade Time Type Quantity Stock Price Currency
12:09:06 600 $ 0.565 USD

Bioxytran (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 48.19M 85.30M $ -296.42k - - 9.78M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.64k $ - 0.00% - -

more financials information »

Bioxytran (QB) News

Loading Messages....

Latest BIXT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIXT Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.610.720.5650.70365k-0.045-7.38%
1 Month0.90.90.5650.70753k-0.335-37.22%
3 Months0.8651.30.5650.81614k-0.3-34.68%
6 Months0.411.950.410.95344k0.15537.80%
1 Year0.511.950.20.80623k0.05510.78%
3 Years0.0441.950.00610.061931k0.5211,184.09%
5 Years0.11.950.00610.087530k0.465465.00%

Bioxytran (QB) Description

Bioxytran Inc., a developmental stage biotechnology company, is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule that seems to reverse hypoxia, or oxygen deficiency. During a hypothetical treatment following hypoxic brain injuries such as ischemic strokes, this molecule could be injected intravenously and then bind with oxygen molecules in the lungs in order to carry the oxygen and deliver it to the area blocked by a blood clot.


Your Recent History
USOTC
BIXT
Bioxytran ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.